Compare Stocks → Trending Stocks Sent To You In Real Time (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGTCNASDAQ:BVXVNASDAQ:CSBRNASDAQ:GMDANASDAQ:LJPC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTCApplied Genetic Technologies$0.39$0.39$0.23▼$2.83$26.62M1.55943,490 shsN/ABVXVBiondVax Pharmaceuticals$1.36$1.25▼$11.80$2.54M2.37127,289 shs23,000 shsCSBRChampions Oncology$5.03+0.2%$10.15$7.19▼$14.68$68.36M0.45,747 shs937 shsGMDAGamida Cell$0.06-82.5%$0.36$0.05▼$2.51$6.25M1.034.89 million shs124.37 million shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTCApplied Genetic Technologies0.00%0.00%0.00%0.00%0.00%BVXVBiondVax Pharmaceuticals0.00%0.00%0.00%0.00%-35.24%CSBRChampions Oncology+0.20%-4.91%-15.46%-7.02%+23.28%GMDAGamida Cell-82.74%-84.26%-84.42%-85.28%-92.24%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%Trending Stocks Sent To You In Real Time (Ad)Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar! Click To Get Our Next AlertMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACSBRChampions Oncology3.9071 of 5 stars3.33.00.04.50.04.20.0GMDAGamida Cell1.4919 of 5 stars3.42.00.00.02.20.80.6LJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTCApplied Genetic TechnologiesN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/ACSBRChampions Oncology2.50Moderate Buy$7.5049.11% UpsideGMDAGamida Cell2.75Moderate Buy$4.757,923.65% UpsideLJPCLa Jolla PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest LJPC, AGTC, GMDA, CSBR, and BVXV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2024CSBRChampions OncologyCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold1/29/2024GMDAGamida CellJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTCApplied Genetic Technologies$320K83.19N/AN/A$0.26 per share1.51BVXVBiondVax PharmaceuticalsN/AN/AN/AN/A($3.81) per shareN/ACSBRChampions Oncology$53.87M1.27N/AN/A($0.15) per share-33.53GMDAGamida CellN/AN/AN/AN/A($0.11) per shareN/ALJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTCApplied Genetic Technologies-$68.94M-$1.46N/AN/AN/AN/A-192.90%-92.54%N/ABVXVBiondVax Pharmaceuticals-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/ACSBRChampions Oncology-$5.34M-$0.72N/A∞N/A-19.76%-850.72%-32.62%7/22/2024 (Estimated)GMDAGamida Cell-$79.38M-$0.30N/AN/AN/AN/AN/A-66.89%N/ALJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTCApplied Genetic TechnologiesN/AN/AN/AN/AN/ABVXVBiondVax PharmaceuticalsN/AN/AN/AN/AN/ACSBRChampions OncologyN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTCApplied Genetic Technologies0.391.401.40BVXVBiondVax PharmaceuticalsN/A4.124.12CSBRChampions OncologyN/A0.600.60GMDAGamida Cell213.143.323.20LJPCLa Jolla PharmaceuticalN/A4.023.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTCApplied Genetic Technologies22.05%BVXVBiondVax Pharmaceuticals11.83%CSBRChampions Oncology41.30%GMDAGamida Cell50.34%LJPCLa Jolla Pharmaceutical97.06%Insider OwnershipCompanyInsider OwnershipAGTCApplied Genetic Technologies4.10%BVXVBiondVax Pharmaceuticals6.03%CSBRChampions Oncology45.69%GMDAGamida Cell6.72%LJPCLa Jolla Pharmaceutical36.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGTCApplied Genetic Technologies8367.63 million64.86 millionOptionableBVXVBiondVax Pharmaceuticals331.87 million1.76 millionNot OptionableCSBRChampions Oncology14313.59 million7.38 millionOptionableGMDAGamida Cell143105.59 million98.49 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableLJPC, AGTC, GMDA, CSBR, and BVXV HeadlinesSourceHeadlineLa Jolla small business owners want lawful path to conduct business on the beachmsn.com - March 27 at 1:40 PMScripps Seaside Forumscripps.ucsd.edu - February 12 at 3:13 PMScripps Green Hospitalhealth.usnews.com - December 19 at 11:27 PM‘We may have to pull the plug’: La Jolla Christmas Parade running short of funds for Dec. 3 eventsandiegouniontribune.com - December 4 at 7:24 PM‘We lost all our fuel’: Pilot killed when small Cessna crashes in La Jollasandiegouniontribune.com - November 24 at 6:32 PMPilot killed in La Jolla neighborhood plane crash identified as Carlsbad mansandiegouniontribune.com - November 24 at 6:32 PMLa Jolla Halloween Events 2023: Trick-Or-Treats & Pumpkin Patchespatch.com - October 28 at 7:51 PMLa Jolla Pharmaceutical (NASDAQ: LJPC)fool.com - September 25 at 7:30 PMLa Jolla BJ's Hoppy Hawaiian Shirts To Benefit Maui Recovery Effortpatch.com - September 14 at 7:50 PMHepatorenal Syndrome Treatment Global Market Report 2023finance.yahoo.com - July 27 at 2:22 AMFireworks Near Me: La Jolla July 4th Events 2023patch.com - July 17 at 7:59 AMDonors Needed In La Jolla To Prevent Red Cross Blood Shortagepatch.com - July 15 at 8:21 AM2 La Jolla Students Receive 2023 National Merit Scholarshipspatch.com - July 15 at 1:10 AMJuly 4th Fireworks 2023 Near La Jollapatch.com - July 1 at 1:25 AMThalassemia Market Research | 2023-2030marketwatch.com - May 16 at 8:59 AMResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...businesswire.com - May 11 at 8:36 PMKidney (Renal) Fibrosis Market Report | Research Across The World 2031marketwatch.com - May 10 at 10:18 AMKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031marketwatch.com - May 8 at 12:20 AMBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.marketwatch.com - May 5 at 9:20 PMFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031marketwatch.com - May 4 at 1:46 PMLa Jolla High Schoolusnews.com - May 3 at 10:44 PMLa Jolla aesthetician building confidence for homeless through nonprofitktvz.com - May 3 at 2:32 AMCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?markets.businessinsider.com - April 19 at 1:55 PMInnoviva Stock Trading Halted Todayjoplinglobe.com - April 17 at 10:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApplied Genetic TechnologiesNASDAQ:AGTCApplied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.BiondVax PharmaceuticalsNASDAQ:BVXVBiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.Champions OncologyNASDAQ:CSBRChampions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.Gamida CellNASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.